Recent Quotes

My Watchlist

Indicators

Bristol-Myers Squibb (NY: BMY )

59.14 +2.05 (+3.59%)

Official Closing Price Updated: 7:00 PM EST, Jan 23, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	14,504,013
Open	57.14
Bid (Size)	59.22 (1)
Ask (Size)	59.25 (4)
Prev. Close	57.09
Today's Range	57.02 - 59.25
52wk Range	39.35 - 61.08
Shares Outstanding	2,222,113,553
Dividend Yield	4.06%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst

January 22, 2025

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals.

Via Benzinga

Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus

January 22, 2025

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:GSK),(NASDAQ:AZN),(NASDAQ:GILD),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Performance

YTD	+4.14%	+4.14%
1 Month	+2.39%	+2.39%
3 Month	+11.75%	+11.75%
6 Month	+30.64%	+30.64%
1 Year	+17.71%	+17.71%

More News

Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?

January 10, 2025

Via Benzinga

This Unpopular Dividend Stock Is a Buy

January 09, 2025

Via The Motley Fool

Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?

December 31, 2024

Via Benzinga

Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus

January 22, 2025

From FN Media Group LLC

Via GlobeNewswire

Peering Into Bristol-Myers Squibb's Recent Short Interest

December 31, 2024

Via Benzinga

2 High-Yield Dividend Stocks to Buy Early in 2025

December 31, 2024

Via The Motley Fool

Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt

January 17, 2025

Via Benzinga

January 17, 2025

Via Benzinga

Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal

January 13, 2025

Via Benzinga

ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors

January 13, 2025

From Arsenal Biosciences

Via GlobeNewswire

Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference

January 09, 2025

Via Benzinga

Alger Launches Russell Innovation ETF To Capitalize On Emerging Innovators

January 08, 2025

Via Benzinga

Salesforce To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday

January 08, 2025

Via Benzinga

3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade

January 04, 2025

Via The Motley Fool

Deal Dispatch: Vera Bradley Is A Mixed Bag, Modell's Ex-CEO Explores Party City

January 03, 2025

Via Benzinga

Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference

January 03, 2025

From Bristol Myers Squibb

Via Business Wire

U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2

December 27, 2024

From Bristol Myers Squibb

Via Business Wire

Exploring BRISTOL-MYERS SQUIBB CO's Technical Signals and Breakout Potential.

December 27, 2024

Via Chartmill

Schwab US Dividend Equity ETF Reverses In December: What's Going On?

December 23, 2024

Via Benzinga

Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis

December 23, 2024

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

December 23, 2024

From Bristol Myers Squibb

Via Business Wire

Got $500? This Top Dividend ETF Is a Great Buy After Its Recent Sell-Off.

December 23, 2024

Via The Motley Fool

Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More

December 22, 2024

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.